Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 2/20 | 0.47 |
| ▸ | DHFR | P00374 | 12/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648993 | 0.85 | DHFR (0.55) | DCPSDHFRKCNH2 | |
| SCHEMBL30482752 | 0.84 | DHFR (0.58) | DCPSDHFRKCNH2 | |
| SCHEMBL30125151 | 0.84 | DHFR (0.58) | DCPSDHFRKCNH2 | |
| SCHEMBL30482758 | 0.84 | DHFR (0.58) | DCPSDHFRKCNH2CYP1A1CYP1A2 | |
| SCHEMBL30482707 | 0.84 | DHFR (0.58) | DCPSDHFRKCNH2 | |
| SCHEMBL30482755 | 0.80 | DHFR (0.61) | DCPSDHFRKCNH2 | |
| SCHEMBL30482737 | 0.80 | DHFR (0.61) | DCPSDHFRKCNH2CYP1A1CYP1A2 | |
| SCHEMBL30482717 | 0.80 | DHFR (0.61) | DCPSDHFRKCNH2 | |
| SCHEMBL30482722 | 0.77 | DHFR (0.45) | DCPSDHFRKCNH2 | |
| SCHEMBL19826965 | 0.77 | DHFR (0.54) | DCPSDHFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2021-11-18 | — | — | US | disclosed |
| WO-2019204768-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | ADRB1, ADRB2, ADRA2B | DCPS 3833/4885DHFR 2861/4885KCNH2 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.